---
title: "CMBI Raises INNOCARE  TP to HKD18.9, Maintains Buy Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303522531.md"
description: "CMBI raised INNOCARE's target price to HKD18.9, maintaining a Buy rating. The upgrade reflects strong H1-H3 revenue growth of 88.2% YoY and a turnaround to net profit. Key drivers include a strategic licensing agreement with Eli Lilly for up to five projects, adding USD100 million in upfront/milestone payments and potential USD3.3 billion in future milestones, validating the company's discovery capabilities."
datetime: "2026-10-29T08:20:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303522531.md)
  - [en](https://longbridge.com/en/news/303522531.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303522531.md)
generator: "portal-rs"
---

# CMBI Raises INNOCARE  TP to HKD18.9, Maintains Buy Rating

CMBI released a report stating that INNOCARE (09969.HK) +0.050 (+0.429%) Short selling $3.79M; Ratio 13.585% 's revenue for the first nine months of this year reached RMB2.1 billion, up 88.2% YoY. During the period, drug sales contributed RMB1.45 billion, up 41.5% YoY, equivalent to 73% of the broker's full-year forecast and in line with expectations.

For 3Q alone, revenue reached RMB962 million, of which drug sales amounted to RMB531 million, up 38.6% YoY and 13.8% QoQ. Net profit for the first nine months was RMB648 million, compared with a loss of RMB72 million in the same period last year, while operating cash flow also turned positive to RMB220 million.

The broker noted that the company recently entered into a strategic licensing agreement with Eli Lilly, covering up to five innovative target projects, providing external validation for the company's discovery capabilities. After factoring in the impact of an upfront payment and near-term milestone payments totaling USD100 million, as well as potential milestone payments of USD3.3 billion, the target price was raised from HKD18.31 to HKD18.9, while the Buy rating was maintained. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-10-29 12:25.)

### Related Stocks

- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)

## Related News & Research

- [InnoCare Doses First Patient in Phase I Trial of Cancer Drug ICP-B381 in China](https://longbridge.com/en/news/305175446.md)
- [InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization](https://longbridge.com/en/news/303068907.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [NetEase Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into NetEase (NTES)](https://longbridge.com/en/news/306200520.md)
- [2026 ASH Oral Presentation | InnoCare Announces Phase III Results of Orelabrutinib in ITP Study Meet Primary Endpoint](https://longbridge.com/en/news/304435812.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**